Primary effusion lymphoma: A liquid phase lymphoma of fluid-filled body cavities

Gianluca Gaidano, Antonino Carbone

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Primary effusion lymphoma (PEL) is a B-cell neoplasm characterized by infection of the tumor clone by human herpesvirus type-8/Kaposi's sarcoma-associated herpesvirus (HHV-8/KSHV) and by liquid growth in fluid-filled body spaces. During its entire clinical course, the lymphoma tends to remain localized to the serous body cavities with no formation of solid tumor masses. The epidemiology of PEL points to a close link with underlying immunodeficiency of the host, as most cases develop in individuals severely immunocompromised because of preexisting acquired immunodeficiency syndrome. The histogenesis and pathogenesis of PEL have been clarified to a sizeable extent by intensive investigations performed since the disease recognition in 1995. PEL is composed of postgerminal center B cells, which bridge immunoblastic and anaplastic features and typically display a non-B, non-T phenotype consistent with late stages of B-cell differentiation. HHV-8/KSHV is thought to play a major role in PEL pathogenesis via expression of several viral latent genes, which have the potential to affect B-cell growth. Other factors involved in PEL pathogenesis include deregulation of cytokine and growth factor autocrine loops, molecular alterations of the tumor DNA, cell cycle abnormalities, stimulation and selection by antigen, and infection by Epstein-Barr virus, which occurs in 70% of PEL cases. In the years since the disease discovery, the distinctiveness of the biological and clinicopathological features of PEL has prompted its recognition as an independent lymphoma category by the World Health Organization classification system of hematologic neoplasms. (C) 2001 Academic Press.

Original languageEnglish
Pages (from-to)115-146
Number of pages32
JournalAdvances in Cancer Research
Volume80
Publication statusPublished - 2000

Fingerprint

Primary Effusion Lymphoma
Body Fluids
Lymphoma
Human Herpesvirus 8
B-Lymphocytes
Neoplasms
Epstein-Barr Virus Infections
Viral Genes
Hematologic Neoplasms
Growth
Cell Differentiation
Intercellular Signaling Peptides and Proteins
Cell Cycle
Acquired Immunodeficiency Syndrome
Epidemiology
Clone Cells
Cytokines
Phenotype
Antigens

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Primary effusion lymphoma : A liquid phase lymphoma of fluid-filled body cavities. / Gaidano, Gianluca; Carbone, Antonino.

In: Advances in Cancer Research, Vol. 80, 2000, p. 115-146.

Research output: Contribution to journalArticle

Gaidano, Gianluca ; Carbone, Antonino. / Primary effusion lymphoma : A liquid phase lymphoma of fluid-filled body cavities. In: Advances in Cancer Research. 2000 ; Vol. 80. pp. 115-146.
@article{8d09ec0b8900425795537ae425aee849,
title = "Primary effusion lymphoma: A liquid phase lymphoma of fluid-filled body cavities",
abstract = "Primary effusion lymphoma (PEL) is a B-cell neoplasm characterized by infection of the tumor clone by human herpesvirus type-8/Kaposi's sarcoma-associated herpesvirus (HHV-8/KSHV) and by liquid growth in fluid-filled body spaces. During its entire clinical course, the lymphoma tends to remain localized to the serous body cavities with no formation of solid tumor masses. The epidemiology of PEL points to a close link with underlying immunodeficiency of the host, as most cases develop in individuals severely immunocompromised because of preexisting acquired immunodeficiency syndrome. The histogenesis and pathogenesis of PEL have been clarified to a sizeable extent by intensive investigations performed since the disease recognition in 1995. PEL is composed of postgerminal center B cells, which bridge immunoblastic and anaplastic features and typically display a non-B, non-T phenotype consistent with late stages of B-cell differentiation. HHV-8/KSHV is thought to play a major role in PEL pathogenesis via expression of several viral latent genes, which have the potential to affect B-cell growth. Other factors involved in PEL pathogenesis include deregulation of cytokine and growth factor autocrine loops, molecular alterations of the tumor DNA, cell cycle abnormalities, stimulation and selection by antigen, and infection by Epstein-Barr virus, which occurs in 70{\%} of PEL cases. In the years since the disease discovery, the distinctiveness of the biological and clinicopathological features of PEL has prompted its recognition as an independent lymphoma category by the World Health Organization classification system of hematologic neoplasms. (C) 2001 Academic Press.",
author = "Gianluca Gaidano and Antonino Carbone",
year = "2000",
language = "English",
volume = "80",
pages = "115--146",
journal = "Advances in Cancer Research",
issn = "0065-230X",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Primary effusion lymphoma

T2 - A liquid phase lymphoma of fluid-filled body cavities

AU - Gaidano, Gianluca

AU - Carbone, Antonino

PY - 2000

Y1 - 2000

N2 - Primary effusion lymphoma (PEL) is a B-cell neoplasm characterized by infection of the tumor clone by human herpesvirus type-8/Kaposi's sarcoma-associated herpesvirus (HHV-8/KSHV) and by liquid growth in fluid-filled body spaces. During its entire clinical course, the lymphoma tends to remain localized to the serous body cavities with no formation of solid tumor masses. The epidemiology of PEL points to a close link with underlying immunodeficiency of the host, as most cases develop in individuals severely immunocompromised because of preexisting acquired immunodeficiency syndrome. The histogenesis and pathogenesis of PEL have been clarified to a sizeable extent by intensive investigations performed since the disease recognition in 1995. PEL is composed of postgerminal center B cells, which bridge immunoblastic and anaplastic features and typically display a non-B, non-T phenotype consistent with late stages of B-cell differentiation. HHV-8/KSHV is thought to play a major role in PEL pathogenesis via expression of several viral latent genes, which have the potential to affect B-cell growth. Other factors involved in PEL pathogenesis include deregulation of cytokine and growth factor autocrine loops, molecular alterations of the tumor DNA, cell cycle abnormalities, stimulation and selection by antigen, and infection by Epstein-Barr virus, which occurs in 70% of PEL cases. In the years since the disease discovery, the distinctiveness of the biological and clinicopathological features of PEL has prompted its recognition as an independent lymphoma category by the World Health Organization classification system of hematologic neoplasms. (C) 2001 Academic Press.

AB - Primary effusion lymphoma (PEL) is a B-cell neoplasm characterized by infection of the tumor clone by human herpesvirus type-8/Kaposi's sarcoma-associated herpesvirus (HHV-8/KSHV) and by liquid growth in fluid-filled body spaces. During its entire clinical course, the lymphoma tends to remain localized to the serous body cavities with no formation of solid tumor masses. The epidemiology of PEL points to a close link with underlying immunodeficiency of the host, as most cases develop in individuals severely immunocompromised because of preexisting acquired immunodeficiency syndrome. The histogenesis and pathogenesis of PEL have been clarified to a sizeable extent by intensive investigations performed since the disease recognition in 1995. PEL is composed of postgerminal center B cells, which bridge immunoblastic and anaplastic features and typically display a non-B, non-T phenotype consistent with late stages of B-cell differentiation. HHV-8/KSHV is thought to play a major role in PEL pathogenesis via expression of several viral latent genes, which have the potential to affect B-cell growth. Other factors involved in PEL pathogenesis include deregulation of cytokine and growth factor autocrine loops, molecular alterations of the tumor DNA, cell cycle abnormalities, stimulation and selection by antigen, and infection by Epstein-Barr virus, which occurs in 70% of PEL cases. In the years since the disease discovery, the distinctiveness of the biological and clinicopathological features of PEL has prompted its recognition as an independent lymphoma category by the World Health Organization classification system of hematologic neoplasms. (C) 2001 Academic Press.

UR - http://www.scopus.com/inward/record.url?scp=0033757148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033757148&partnerID=8YFLogxK

M3 - Article

C2 - 11034542

AN - SCOPUS:0033757148

VL - 80

SP - 115

EP - 146

JO - Advances in Cancer Research

JF - Advances in Cancer Research

SN - 0065-230X

ER -